Search

Your search keyword '"Groll, Andreas H."' showing total 1,048 results
Start Over Author "Groll, Andreas H."
1,048 results on '"Groll, Andreas H."'

1. School and kindergarten attendance and home schooling of pediatric cancer patients before and during the SARS-CoV-2 pandemic: results of a survey of the German Society for Pediatric Oncology and Hematology

Author

Simon, Arne, Siebald, Benjamin, Stamm, Walther, Graf, Norbert, Meier, Stephan, Schrappe, Martin, Groll, Andreas H., Laws, Hans-Jürgen, and Lehrnbecher, Thomas

Subjects
children with cancer, infection prevention, sars-cov-2, school, day care center, home schooling, Medicine, Public aspects of medicine, RA1-1270, Microbiology, QR1-502
Abstract

In this multicenter survey (July 07 to August 08, 2020) in pediatric oncology centers (POCs) belonging to the German Society for Pediatric Oncology and Hematology (GPOH), 36 POCs participated (response rate 70.6%). Home schooling practice was judged as satisfying by 79% prior to and by 38% during the pandemic (=0.0007). The individual risk of a SARS-CoV-2 infection and the risk of transmission to other patients/caregivers were arguments against attendance. Most POCs recommended regular social participation/school attendance after the end of intensive therapy. 81% stated that persisting restrictions result in serious negative psychosocial consequences for the patients and their families. In-hospital school education, home schooling and re-attendance of school and kindergarten among pediatric cancer patients have suffered a severe setback during the SARS-CoV-2 pandemic. Continuous communication and education concerning protective measures as well as an individual risk assessment are required to avoid the detrimental exclusion of pediatric oncology patients from kindergarten and school.

Published
2021
Full Text
View/download PDF

3. Antifungal Drug Usage in European Neonatal Units: A Multicenter Weekly Point Prevalence Study

Author

Chorafa, Elisavet, Iosifidis, Elias, Oletto, Andrea, Warris, Adilia, Castagnola, Elio, Bruggemann, Roger, Groll, Andreas H., Lehrnbecher, Thomas, Ferreras Antolin, Laura, Mesini, Alessio, Agakidou, Eleni, Controzzi, Tiziana, De Luca, Maia, Dimitriou, Gabriel, Emonts, Marieke, Esposito, Susanna, Fernàndez-Polo, Aurora, Ghimenton-Walters, Elisabetta, Gkentzi, Despoina, Grasa, Carlos, Hatzidaki, Eleftheria, Jõgi, Piia, Kildonaviciute, Kornelija, Kontou, Angeliki, Leibold-Aguinarte, Alessa, Manzanares, Angela, Mendoza-Palomar, Natalia, Metsvaht, Tuuli, Noni, Maria, Paulus, Stéphane, Perrone, Serafina, Rincón-López, Elena, Romani, Lorenza, Sánchez, Laura, Cetin, Benhur Sirvan, Spoulou, Vana, Strenger, Volker, Vergadi, Eleni, Villaverde, Serena, Vuerich, Marco, Zamora-Flores, Elena, Roilides, Emmanuel, Fainardi, Valentina, Ramundo, Greta, Alkhaaldi, Aisha Abdalla, Tedford, Kara, Butler, Karina, Solopova, Galina, Zsigmond, Borbala, Szekeres, Klaudia, Sarafidis, Kosmas, Sdougka, Maria, Papakonstantinou, Eugenia, Papadimitriou, Eleni, Tsikopoulos, George, Gijón, Manuel, Arias, Ana, Rojo, Pablo, González Guerrero, Alba, Herrera-Castillo, Laura, Chamorro-de-Vega, Esther, Grasa, Carlos D., Moreno-Ramos, Francisco, Baquero-Artigao, Fernando, Soler-Palacin, Pere, Melendo, Susana, Martín-Gómez, Maria Teresa, Keldorfer, Markus, Morris, Nicholas M., Perwein, Thomas, Gordon, Kathrin, Ebrahimi-Fakhari, Daniel, Masjosthusmann, Katja, Rascon, Jelena, and Kairiene, Igne

Published
2024
Full Text
View/download PDF

4. Safety and outcome of treatment with voriconazole in a large cohort of immunocompromised children and adolescents

Author

Pieper, Stephanie, Kolve, Hedwig, Meine, Timo, Goletz, Grazyna, and Groll, Andreas H.

Subjects
mycoses, children, cancer, voriconazole, safety, Infectious and parasitic diseases, RC109-216
Abstract

Objectives: Post-marketing data on safety and outcome of voriconazole (VCZ) treatment in pediatric patients is limited. We performed a retrospective, single center analysis of safety, tolerance and antifungal efficacy in a large cohort of children and adolescents requiring VCZ therapy.Patients and methods: The cohort included 107 patients (0.2–18 years of age) with hematological disorders (85; 42 post allo-HSCT), primary immunodeficiencies (9), AIDS (4), metabolic diseases (5) and solid tumors (4) who received 252 courses of VCZ for possible (12) and probable/proven (25) invasive fungal diseases (IFDs), as primary (127) or secondary (79) prophylaxis or as empiric therapy (9). VCZ was given IV (10) and (37)/or (205) PO at recommended dosages until intolerance or maximum efficacy. IFDs and outcomes were assessed by EORTC/MSG consensus criteria.Results: VCZ was administered at a median maintenance dosage of 5.9 mg/kg twice daily (range, 2.2–22.0) for a median of 65 days (range 1–1,002). While on treatment, increases in hepatic transaminases, serum bilirubin and alkaline phosphatase, skin eruptions and neurological adverse events (AEs) were observed in 53.5, 23.6, 10.9, 5.6 and 4.8% of courses, respectively. At end of treatment (EOT), mean alkaline phosphatase, aspartate aminotransferase and serum bilirubin values were slightly elevated relative to baseline (p

Published
2015
Full Text
View/download PDF

7. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM

Author

Chang, Christina C, Harrison, Thomas S, Bicanic, Tihana A, Chayakulkeeree, Methee, Sorrell, Tania C, Warris, Adilia, Hagen, Ferry, Spec, Andrej, Oladele, Rita, Govender, Nelesh P, Chen, Sharon C, Mody, Christopher H, Groll, Andreas H, Chen, Yee-Chun, Lionakis, Michail S, Alanio, Alexandre, Castañeda, Elizabeth, Lizarazo, Jairo, Vidal, José E, Takazono, Takahiro, Hoenigl, Martin, Alffenaar, Jan-Willem, Gangneux, Jean-Pierre, Soman, Rajeev, Zhu, Li-Ping, Bonifaz, Alexandro, Jarvis, Joseph N, Day, Jeremy N, Klimko, Nikolai, Salmanton-García, Jon, Jouvion, Grégory, Meya, David B, Lawrence, David, Rahn, Sebastian, Bongomin, Felix, McMullan, Brendan J, Sprute, Rosanne, Nyazika, Tinashe K, Beardsley, Justin, Carlesse, Fabianne, Heath, Christopher H, Ayanlowo, Olusola O, Mashedi, Olga M, Queiroz-Telles Filho, Flavio, Hosseinipour, Mina C, Patel, Atul K, Temfack, Elvis, Singh, Nina, Cornely, Oliver A, Boulware, David R, Lortholary, Olivier, Pappas, Peter G, and Perfect, John R

Published
2024
Full Text
View/download PDF

8. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022

Author

Aerts, Robina, Mehra, Varun, Groll, Andreas H, Martino, Rodrigo, Lagrou, Katrien, Robin, Christine, Perruccio, Katia, Blijlevens, Nicole, Nucci, Marcio, Slavin, Monica, Bretagne, Stéphane, and Cordonnier, Catherine

Published
2024
Full Text
View/download PDF

9. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author

Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart JA, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A

Subjects
Infectious Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Antifungal Agents, Aspergillosis, Bronchoalveolar Lavage Fluid, Humans, Immunocompromised Host, Invasive Fungal Infections, Invasive Pulmonary Aspergillosis, Mannans, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2021

10. Pediatric Cryptococcosis

Author

Gifford, Alison, Jayawardena, Naamal, Carlesse, Fabianne, Lizarazo, Jairo, McMullan, Brendan, Groll, Andreas H., and Warris, Adilia

Published
2024
Full Text
View/download PDF

15. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J Peter, Chen, Sharon C, Kauffman, Carol A, Steinbach, William J, Baddley, John W, Verweij, Paul E, Clancy, Cornelius J, Wingard, John R, Lockhart, Shawn R, Groll, Andreas H, Sorrell, Tania C, Bassetti, Matteo, Akan, Hamdi, Alexander, Barbara D, Andes, David, Azoulay, Elie, Bialek, Ralf, Bradsher, Robert W, Bretagne, Stephane, Calandra, Thierry, Caliendo, Angela M, Castagnola, Elio, Cruciani, Mario, Cuenca-Estrella, Manuel, Decker, Catherine F, Desai, Sujal R, Fisher, Brian, Harrison, Thomas, Heussel, Claus Peter, Jensen, Henrik E, Kibbler, Christopher C, Kontoyiannis, Dimitrios P, Kullberg, Bart-Jan, Lagrou, Katrien, Lamoth, Frédéric, Lehrnbecher, Thomas, Loeffler, Jurgen, Lortholary, Olivier, Maertens, Johan, Marchetti, Oscar, Marr, Kieren A, Masur, Henry, Meis, Jacques F, Morrisey, C Orla, Nucci, Marcio, Ostrosky-Zeichner, Luis, Pagano, Livio, Patterson, Thomas F, Perfect, John R, Racil, Zdenek, Roilides, Emmanuel, Ruhnke, Marcus, Prokop, Cornelia Schaefer, Shoham, Shmuel, Slavin, Monica A, Stevens, David A, Thompson, George R, Vazquez, Jose A, Viscoli, Claudio, Walsh, Thomas J, Warris, Adilia, Wheat, L Joseph, White, P Lewis, Zaoutis, Theoklis E, and Pappas, Peter G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Prevention, Clinical Research, Good Health and Well Being, Antifungal Agents, Consensus, Humans, Immunocompromised Host, Invasive Fungal Infections, Mycoses, Neoplasms, consensus, definitions, invasive fungal diseases, diagnosis, research, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundInvasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.MethodsTo achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.ResultsThere is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.ConclusionsThese updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

16. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Author

Cornely, Oliver A, Alastruey-Izquierdo, Ana, Arenz, Dorothee, Chen, Sharon CA, Dannaoui, Eric, Hochhegger, Bruno, Hoenigl, Martin, Jensen, Henrik E, Lagrou, Katrien, Lewis, Russell E, Mellinghoff, Sibylle C, Mer, Mervyn, Pana, Zoi D, Seidel, Danila, Sheppard, Donald C, Wahba, Roger, Akova, Murat, Alanio, Alexandre, Al-Hatmi, Abdullah MS, Arikan-Akdagli, Sevtap, Badali, Hamid, Ben-Ami, Ronen, Bonifaz, Alexandro, Bretagne, Stéphane, Castagnola, Elio, Chayakulkeeree, Methee, Colombo, Arnaldo L, Corzo-León, Dora E, Drgona, Lubos, Groll, Andreas H, Guinea, Jesus, Heussel, Claus-Peter, Ibrahim, Ashraf S, Kanj, Souha S, Klimko, Nikolay, Lackner, Michaela, Lamoth, Frederic, Lanternier, Fanny, Lass-Floerl, Cornelia, Lee, Dong-Gun, Lehrnbecher, Thomas, Lmimouni, Badre E, Mares, Mihai, Maschmeyer, Georg, Meis, Jacques F, Meletiadis, Joseph, Morrissey, C Orla, Nucci, Marcio, Oladele, Rita, Pagano, Livio, Pasqualotto, Alessandro, Patel, Atul, Racil, Zdenek, Richardson, Malcolm, Roilides, Emmanuel, Ruhnke, Markus, Seyedmousavi, Seyedmojtaba, Sidharthan, Neeraj, Singh, Nina, Sinko, János, Skiada, Anna, Slavin, Monica, Soman, Rajeev, Spellberg, Brad, Steinbach, William, Tan, Ban Hock, Ullmann, Andrew J, Vehreschild, Jörg J, Vehreschild, Maria JGT, Walsh, Thomas J, White, P Lewis, Wiederhold, Nathan P, Zaoutis, Theoklis, Chakrabarti, Arunaloke, and Group, Mucormycosis ECMM MSG Global Guideline Writing

Subjects
Clinical Research, Good Health and Well Being, Disease Management, Humans, Mucormycosis, Mucormycosis ECMM MSG Global Guideline Writing Group, Clinical Sciences, Medical Microbiology, Public Health and Health Services, Microbiology
Abstract

Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the "One World One Guideline" initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.

Published
2019

19. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.

Author

Arrieta, Antonio C, Sung, Lillian, Bradley, John S, Zwaan, C Michel, Gates, Davis, Waskin, Hetty, Carmelitano, Patricia, Groll, Andreas H, Lehrnbecher, Thomas, Mangin, Eric, Joshi, Amita, Kartsonis, Nicholas A, Walsh, Thomas J, and Paschke, Amanda

Subjects
Humans, Neoplasms, Neutropenia, Triazoles, Antineoplastic Agents, Antifungal Agents, Administration, Oral, Drug Administration Schedule, Area Under Curve, Prospective Studies, Age Factors, Immunocompromised Host, Dose-Response Relationship, Drug, Adolescent, Child, Child, Preschool, Infant, Female, Male, Invasive Fungal Infections, Administration, Oral, Preschool, Dose-Response Relationship, Drug, General Science & Technology
Abstract

BACKGROUND:Posaconazole (POS) is a potent triazole antifungal agent approved in adults for treatment and prophylaxis of invasive fungal infections (IFIs). The objectives of this study were to evaluate the pharmacokinetics (PK), safety, and tolerability of POS oral suspension in pediatric subjects with neutropenia. METHODS:This was a prospective, multicenter, sequential dose-escalation study. Enrolled subjects were divided into 3 age groups: AG1, 7 to

Published
2019

22. Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM

Author

Chen, Sharon C-A, Perfect, John, Colombo, Arnaldo L, Cornely, Oliver A, Groll, Andreas H, Seidel, Danila, Albus, Kerstin, de Almedia, Joao N, Jr, Garcia-Effron, Guillermo, Gilroy, Nicole, Lass-Flörl, Cornelia, Ostrosky-Zeichner, Luis, Pagano, Livio, Papp, Tamas, Rautemaa-Richardson, Riina, Salmanton-García, Jon, Spec, Andrej, Steinmann, Joerg, Arikan-Akdagli, Sevtap, Arenz, Dorothee E, Sprute, Rosanne, Duran-Graeff, Luisa, Freiberger, Tomas, Girmenia, Corrado, Harris, Michelle, Kanj, Souha S, Roudbary, Maryam, Lortholary, Olivier, Meletiadis, Joseph, Segal, Esther, Tuon, Felipe Francisco, Wiederhold, Nathan, Bicanic, Tihana, Chander, Jagdish, Chen, Yee-Chun, Hsueh, Po-Ren, Ip, Margaret, Munoz, Patricia, Spriet, Isabel, Temfack, Elvis, Thompson, Luis, Tortorano, Anna Maria, Velegraki, Aristea, and Govender, Nelesh P

Published
2021
Full Text
View/download PDF

25. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease

Author

Hoenigl, Martin, primary, Arastehfar, Amir, additional, Arendrup, Maiken Cavling, additional, Brüggemann, Roger, additional, Carvalho, Agostinho, additional, Chiller, Tom, additional, Chen, Sharon, additional, Egger, Matthias, additional, Feys, Simon, additional, Gangneux, Jean-Pierre, additional, Gold, Jeremy A. W., additional, Groll, Andreas H., additional, Heylen, Jannes, additional, Jenks, Jeffrey D., additional, Krause, Robert, additional, Lagrou, Katrien, additional, Lamoth, Frédéric, additional, Prattes, Juergen, additional, Sedik, Sarah, additional, Wauters, Joost, additional, Wiederhold, Nathan P., additional, and Thompson, George R., additional

Published
2024
Full Text
View/download PDF

26. Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”

Author

de Hoog, Sybren, primary, Walsh, Thomas J., additional, Ahmed, Sarah A., additional, Alastruey-Izquierdo, Ana, additional, Alexander, Barbara D., additional, Arendrup, Maiken Cavling, additional, Babady, Esther, additional, Bai, Feng-Yan, additional, Balada-Llasat, Joan-Miquel, additional, Borman, Andrew, additional, Chowdhary, Anuradha, additional, Clark, Andrew, additional, Colgrove, Robert C., additional, Cornely, Oliver A., additional, Dingle, Tanis C., additional, Dufresne, Philippe J., additional, Fuller, Jeff, additional, Gangneux, Jean-Pierre, additional, Gibas, Connie, additional, Glasgow, Heather, additional, Graser, Yvonne, additional, Guillot, Jacques, additional, Groll, Andreas H., additional, Haase, Gerhard, additional, Hanson, Kimberly, additional, Harrington, Amanda, additional, Hawksworth, David L., additional, Hayden, Randall T., additional, Hoenigl, Martin, additional, Hubka, Vit, additional, Johnson, Kristie, additional, Kus, Julianne V., additional, Li, Ruoyu, additional, Meis, Jacques F., additional, Lackner, Michaela, additional, Lanternier, Fanny, additional, Leal, Sixto M., additional, Lee, Francesca, additional, Lockhart, Shawn R., additional, Luethy, Paul, additional, Martin, Isabella, additional, Kwon-Chung, Kyung J., additional, Meyer, Wieland, additional, Nguyen, M. Hong, additional, Ostrosky-Zeichner, Luis, additional, Palavecino, Elizabeth, additional, Pancholi, Preeti, additional, Pappas, Peter G., additional, Procop, Gary W., additional, Redhead, Scott A., additional, Rhoads, Daniel D., additional, Riedel, Stefan, additional, Stevens, Bryan, additional, Sullivan, Kaede Ota, additional, Vergidis, Paschalis, additional, Roilides, Emmanuel, additional, Seyedmousavi, Amir, additional, Tao, Lili, additional, Vicente, Vania A., additional, Vitale, Roxana G., additional, Wang, Qi-Ming, additional, Wengenack, Nancy L., additional, Westblade, Lars, additional, Wiederhold, Nathan, additional, White, Lewis, additional, Wojewoda, Christina M., additional, and Zhang, Sean X., additional

Published
2024
Full Text
View/download PDF

27. Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi‐international clinical trial AIEOP‐BFM ALL 2009

Author

Barnbrock, Anke, primary, Möricke, Anja, additional, Barbaric, Draga, additional, Jones, Neil, additional, Koenig, Christa, additional, Moser, Reinhard, additional, Rohde, Marius, additional, Salvador, Christina, additional, Alten, Julia, additional, Elitzur, Sarah, additional, Groll, Andreas H., additional, and Lehrnbecher, Thomas, additional

Published
2024
Full Text
View/download PDF

28. Pneumocystis Pneumonia After Allogeneic Hematopoietic Cell Transplantation: A Case-Control Study on Epidemiology and Risk Factors on Behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Robin, Christine, Cordonnier, Catherine, Tridello, Gloria, Knelange, Nina, Xhaard, Alienor, Chantepie, Sylvain, Tanguy-Schmidt, Aline, Schouten, Harry C., Yeshurun, Moshe, Rocha, Vanderson, Srour, Micha, Kröger, Nicolaus, Ledoux, Marie-Pierre, Dalgaard, Jakob, Thiebaut, Anne, Giardino, Stefano, Calore, Elisabetta, Zuckerman, Tsila, Groll, Andreas H., Raida, Ludek, Avcin, Simona, Vicent, Marta Gonzalez, Kaare, Ain, Drozd-Sokolowska, Joanna, Turlure, Pascal, Bretagne, Stéphane, Mikulska, Malgorzata, Camara, Rafael de la, Cesaro, Simone, and Styczynski, Jan

Published
2024
Full Text
View/download PDF

31. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation

Author

Lehrnbecher, Thomas, Averbuch, Dina, Castagnola, Elio, Cesaro, Simone, Ammann, Roland A, Garcia-Vidal, Carolina, Kanerva, Jukka, Lanternier, Fanny, Mesini, Alessio, Mikulska, Malgorzata, Pana, Dorothea, Ritz, Nicole, Slavin, Monica, Styczynski, Jan, Warris, Adilia, and Groll, Andreas H

Published
2021
Full Text
View/download PDF

32. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation

Author

Groll, Andreas H, Pana, Dorothea, Lanternier, Fanny, Mesini, Alessio, Ammann, Roland A, Averbuch, Dina, Castagnola, Elio, Cesaro, Simone, Engelhard, Dan, Garcia-Vidal, Carolina, Kanerva, Jukka, Ritz, Nicole, Roilides, Emmanuel, Styczynski, Jan, Warris, Adilia, and Lehrnbecher, Thomas

Published
2021
Full Text
View/download PDF

34. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM

Author

MMB, MMB Medische Staf, Chang, Christina C., Harrison, Thomas S., Bicanic, Tihana A., Chayakulkeeree, Methee, Sorrell, Tania C., Warris, Adilia, Hagen, Ferry, Spec, Andrej, Oladele, Rita, Govender, Nelesh P., Chen, Sharon C., Mody, Christopher H., Groll, Andreas H., Chen, Yee Chun, Lionakis, Michail S., Alanio, Alexandre, Castañeda, Elizabeth, Lizarazo, Jairo, Vidal, José E., Takazono, Takahiro, Hoenigl, Martin, Alffenaar, Jan Willem, Gangneux, Jean Pierre, Soman, Rajeev, Zhu, Li Ping, Bonifaz, Alexandro, Jarvis, Joseph N., Day, Jeremy N., Klimko, Nikolai, Salmanton-García, Jon, Jouvion, Grégory, Meya, David B., Lawrence, David, Rahn, Sebastian, Bongomin, Felix, McMullan, Brendan J., Sprute, Rosanne, Nyazika, Tinashe K., Beardsley, Justin, Carlesse, Fabianne, Heath, Christopher H., Ayanlowo, Olusola O., Mashedi, Olga M., Queiroz-Telles Filho, Flavio, Hosseinipour, Mina C., Patel, Atul K., Temfack, Elvis, Singh, Nina, Cornely, Oliver A., Boulware, David R., Lortholary, Olivier, Pappas, Peter G., Perfect, John R., MMB, MMB Medische Staf, Chang, Christina C., Harrison, Thomas S., Bicanic, Tihana A., Chayakulkeeree, Methee, Sorrell, Tania C., Warris, Adilia, Hagen, Ferry, Spec, Andrej, Oladele, Rita, Govender, Nelesh P., Chen, Sharon C., Mody, Christopher H., Groll, Andreas H., Chen, Yee Chun, Lionakis, Michail S., Alanio, Alexandre, Castañeda, Elizabeth, Lizarazo, Jairo, Vidal, José E., Takazono, Takahiro, Hoenigl, Martin, Alffenaar, Jan Willem, Gangneux, Jean Pierre, Soman, Rajeev, Zhu, Li Ping, Bonifaz, Alexandro, Jarvis, Joseph N., Day, Jeremy N., Klimko, Nikolai, Salmanton-García, Jon, Jouvion, Grégory, Meya, David B., Lawrence, David, Rahn, Sebastian, Bongomin, Felix, McMullan, Brendan J., Sprute, Rosanne, Nyazika, Tinashe K., Beardsley, Justin, Carlesse, Fabianne, Heath, Christopher H., Ayanlowo, Olusola O., Mashedi, Olga M., Queiroz-Telles Filho, Flavio, Hosseinipour, Mina C., Patel, Atul K., Temfack, Elvis, Singh, Nina, Cornely, Oliver A., Boulware, David R., Lortholary, Olivier, Pappas, Peter G., and Perfect, John R.

Published
2024

35. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study

Author

Styczyński, Jan, Tridello, Gloria, Xhaard, Alienor, Medinger, Michael, Mielke, Stephan, Taskinen, Mervi, Blijlevens, Nicole, Rodriguez, M. Aranzazu Bermudez, Solano, Carlos, Nikolousis, Emmanouil, Biffi, Alessandra, Groll, Andreas H., Junghanss, Christian, Tsirigotis, Panagiotis, Lioure, Bruno, Šrámek, Jiří, Holler, Ernst, Galaverna, Federica, Fagioli, Franca, Knelange, Nina, Wendel, Lotus, Gil, Lidia, de la Camara, Rafael, Mikulska, Malgorzata, and Ljungman, Per

Published
2021
Full Text
View/download PDF

37. Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients

Author

Groll, Andreas H., primary, Schulte, Johannes H., additional, Antmen, Ali Bülent, additional, Fraser, Christopher J., additional, Teal, Valerie L., additional, Haber, Barbara, additional, Caro, Luzelena, additional, McCrea, Jacqueline B., additional, Fancourt, Craig, additional, Patel, Mayankbhai, additional, Menzel, Karsten, additional, and Badshah, Cyrus, additional

Published
2024
Full Text
View/download PDF

38. Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: A rare but fatal condition

Author

Abele, Michael, primary, Forchhammer, Stephan, additional, Eigentler, Thomas K., additional, Popescu, Aryana, additional, Maschke, Linda, additional, Lohse, Judith, additional, Lehrnbecher, Thomas, additional, Behnisch, Wolfgang, additional, Groll, Andreas H., additional, Jakob, Marcus, additional, Bernbeck, Benedikt, additional, Brecht, Ines B., additional, and Schneider, Dominik T., additional

Published
2024
Full Text
View/download PDF

41. A Prospective, International Cohort Study of Invasive Mold Infections in Children

Author

Wattier, Rachel L, Dvorak, Christopher C, Hoffman, Jill A, Brozovich, Ava A, Bin-Hussain, Ibrahim, Groll, Andreas H, Castagnola, Elio, Knapp, Katherine M, Zaoutis, Theoklis E, Gustafsson, Britt, Sung, Lillian, Berman, David, Halasa, Natasha B, Abzug, Mark J, Velegraki, Aristea, Sharma, Tanvi S, Fisher, Brian T, and Steinbach, William J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Pediatric, Infectious Diseases, Clinical Research, Prevention, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adolescent, Antifungal Agents, Aspergillosis, Child, Child, Preschool, Female, Fungi, Humans, Male, Mycoses, Prospective Studies, Risk Factors, Treatment Outcome, antifungal, aspergillosis, mucormycosis, outcome, treatment, Medical microbiology, Paediatrics
Abstract

BackgroundInvasive mold infections (IMIs) are a leading cause of mortality in immunocompromised children, yet there has never been an international epidemiologic investigation of pediatric IMIs.MethodsThis international, prospective cohort study was performed to characterize the epidemiology, antifungal therapy, and outcomes of pediatric IMIs. Children (≤18 years) with proven or probable IMIs were enrolled between August 2007 and May 2011 at 22 sites. Risk factors, underlying diagnoses, and treatments were recorded. Outcomes were assessed at 12 weeks after diagnosis using European Organization for Research and Treatment of Cancer/Mycoses Study Group response criteria.ResultsOne hundred thirty-one pediatric patients with IMIs were enrolled; the most common IMI was invasive aspergillosis ([IA] 75%). Children with IA and those with other types of IMIs had similar underlying risk factors, except that children with IMIs caused by non-Aspergillus species were more likely to have received mold-active antifungal agents preceding diagnosis. The most commonly used antifungal classes after diagnosis were triazoles (82%) and polyenes (63%). Combination therapy was used in 53% of patients. Use of combination therapy was associated with an increased risk of adverse events (risk ratio, 1.98; 95% confidence interval, 1.06-3.68; P = .031), although there was no detectable difference in outcome.ConclusionsAlthough risk factors for IMIs are similar across specific subtypes, preceding antifungal therapy may be an important modifier. Combination antifungal therapy requires further study to determine its true risks and benefits.

Published
2015

44. 2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study

Author

Schulte, Johannes H, primary, Gefen, Aharon, additional, Groll, Andreas H, additional, Fraser, Christopher J, additional, Teal, Valerie L, additional, Haber, Barbara A, additional, Gilbert, Christopher L, additional, McCrea, Jacqueline B, additional, Patel, Mayankbhai, additional, Menzel, Karsten, additional, and Badshah, Cyrus, additional

Published
2023
Full Text
View/download PDF

45. 1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients

Author

Arrieta, Antonio C, primary, Segers, Heidi, additional, Deville, Jaime G, additional, Muller, William J, additional, Manzanares, Angela, additional, Neely, Michael N, additional, Bordon, Victoria, additional, Hanisch, Benjamin, additional, Lassaletta, Alvaro, additional, Fisher, Brian T, additional, Autmizguine, Julie, additional, Groll, Andreas H, additional, Sinnar, Shamim, additional, Croos-Dabrera, Rodney, additional, Engelhardt, Marc, additional, Jones, Mark E, additional, and Kovanda, Laura, additional

Published
2023
Full Text
View/download PDF

46. Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Robin, Christine, primary, Cordonnier, Catherine, additional, Tridello, Gloria, additional, Knelange, Nina, additional, Xhaard, Alienor, additional, Chantepie, Sylvain, additional, Tanguy-Schmidt, Aline, additional, Schouten, Harry C, additional, Yesherun, Moshe, additional, Rocha, Vanderson, additional, Srour, Micha, additional, Kröger, Nicolaus, additional, Ledoux, Marie-Pierre, additional, Dalgaard, Jakob, additional, Thiebaut, Anne, additional, Giardino, Stefano, additional, Calore, Elisabetta, additional, Zuckerman, Tsila, additional, Groll, Andreas H, additional, Raida, Ludek, additional, Avcin, Simona, additional, Vicent, Marta Gonzalez, additional, Kaare, Ain, additional, Drozd-Sokolowska, Joanna, additional, Turlure, Pascal, additional, Bretagne, Stéphane, additional, Mikulska, Malgorzata, additional, Camara, Rafael de la, additional, Cesaro, Simone, additional, and Styczynski, Jan, additional

Published
2023
Full Text
View/download PDF

47. A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC

Author

de Hoog, Sybren, primary, Walsh, Thomas J., additional, Ahmed, Sarah A., additional, Alastruey-Izquierdo, Ana, additional, Alexander, Barbara D., additional, Arendrup, Maiken Cavling, additional, Babady, Esther, additional, Bai, Feng-Yan, additional, Balada-Llasat, Joan-Miquel, additional, Borman, Andrew, additional, Chowdhary, Anuradha, additional, Clark, Andrew, additional, Colgrove, Robert C., additional, Cornely, Oliver A., additional, Dingle, Tanis C., additional, Dufresne, Philippe J., additional, Fuller, Jeff, additional, Gangneux, Jean-Pierre, additional, Gibas, Connie, additional, Glasgow, Heather, additional, Gräser, Yvonne, additional, Guillot, Jacques, additional, Groll, Andreas H., additional, Haase, Gerhard, additional, Hanson, Kimberly, additional, Harrington, Amanda, additional, Hawksworth, David L., additional, Hayden, Randall T., additional, Hoenigl, Martin, additional, Hubka, Vit, additional, Johnson, Kristie, additional, Kus, Julianne V., additional, Li, Ruoyu, additional, Meis, Jacques F., additional, Lackner, Michaela, additional, Lanternier, Fanny, additional, Leal Jr., Sixto M., additional, Lee, Francesca, additional, Lockhart, Shawn R., additional, Luethy, Paul, additional, Martin, Isabella, additional, Kwon-Chung, Kyung J., additional, Meyer, Wieland, additional, Nguyen, M. Hong, additional, Ostrosky-Zeichner, Luis, additional, Palavecino, Elizabeth, additional, Pancholi, Preeti, additional, Pappas, Peter G., additional, Procop, Gary W., additional, Redhead, Scott A., additional, Rhoads, Daniel D., additional, Riedel, Stefan, additional, Stevens, Bryan, additional, Sullivan, Kaede Ota, additional, Vergidis, Paschalis, additional, Roilides, Emmanuel, additional, Seyedmousavi, Amir, additional, Tao, Lili, additional, Vicente, Vania A., additional, Vitale, Roxana G., additional, Wang, Qi-Ming, additional, Wengenack, Nancy L., additional, Westblade, Lars, additional, Wiederhold, Nathan, additional, White, Lewis, additional, Wojewoda, Christina M., additional, and Zhang, Sean X., additional

Published
2023
Full Text
View/download PDF

48. Pediatric Cancer Patients Vaccinated Against SARS-CoV-2 – A Clinical and Laboratory Follow-Up

Author

Siebald, Benjamin, primary, Groll, Andreas H., additional, Salou, Sarah, additional, Boldt, Andreas, additional, Seiffert, Sabine, additional, Sack, Ulrich, additional, Reemtsma, Judith, additional, Jassoy, Christian, additional, Klusmann, Jan-Henning, additional, Ciesek, Sandra, additional, Hoehl, Sebastian, additional, and Lehrnbecher, Thomas, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results